Suven Life Sciences has registered a rise of 16.21% in net profit to Rs 1.29 crore for the third quarter ended December 31, 2011. The company had posted a net profit of Rs 1.11 crore in the corresponding period of previous fiscal.
The company’s net income from sales and services rose to Rs 48.72 crore for the third quarter, compared to Rs 32.06 crore in the same period previous fiscal, up by 51.97%.
In addition, the company said that with effect from December 31, 2011, Suven Nishtaa Pharma has become a wholly-owned subsidiary of the company. Further, the company said its board at its meeting held on January 31, 2012 has given its consent for amalgamation of Suven Nishtaa Pharma with Suven Life Sciences subject to the approval of the scheme by the High Court of Andhra Pradesh.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: